The Evidence Hierarchy: Ranking Dog Supplement Categories by Scientific Support

Research Analysis · 14 min read

✓ Our Fact-Checking Team — July 30, 2026

Table of Contents

• The Claim Under Review
• The Evidence Hierarchy, Explained
• Applying the Hierarchy to Supplement Categories
• The Category Evidence Master Table
• Why Postbiotics Sit Higher Than Most
• Why Most “Clinically Formulated” Claims Live at Level 4
• How to Use the Hierarchy as a Consumer
• Our Verdict and Why
• Frequently Asked Questions
• References

The Claim Under Review

The supplement category borrows heavily from the language of science. Products are “scientifically formulated,” “research-backed,” and “clinically inspired.” The cumulative effect is an impression that the category as a whole rests on a foundation of clinical proof. This article tests that impression against the tool that medicine uses to grade evidence: the evidence hierarchy.

The question isn’t whether any science exists anywhere relevant to dog supplements — it does. The question is how strong that science is, and at what level of the hierarchy each category actually sits. A finding from a mouse study is real science; it’s simply not the same weight of evidence as a randomized controlled trial in dogs, which isn’t the same weight as a systematic review pooling many such trials. Conflating these levels is the source of a great deal of misleading marketing, a point we’ve made before in our guide to how to read a clinical trial as a dog owner.

The Evidence Hierarchy, Explained

Evidence-based medicine ranks study designs by how much confidence they justify. The standard pyramid, from strongest to weakest, looks like this:

Level 1 — Systematic reviews and meta-analyses

The top of the pyramid. A systematic review identifies all the relevant studies on a question using a pre-defined method, assesses their quality, and — in a meta-analysis — pools their results statistically. Because they synthesize many studies rather than relying on one, they’re the most reliable single source of evidence. A good systematic review can also tell you when the evidence is still weak, which is itself valuable information.

Level 2 — Randomized controlled trials (RCTs)

The gold standard for a single study. Subjects are randomly assigned to a treatment or control (often placebo), ideally blinded, and outcomes are compared. An RCT in the target species — dogs, in this case — is far more informative than one in another species. A handful of well-conducted canine RCTs is strong evidence; a single small RCT is suggestive but not definitive.

Level 3 — Animal models and in-vitro studies

Studies in other species (mice, rats, humans) or in cell cultures. These are genuinely useful for understanding mechanism and generating hypotheses, but they don’t establish that a product works in dogs. A compound that modulates immune cells in a petri dish may do nothing meaningful when fed to a dog at the labeled dose. Most supplement marketing that cites “research” stops here.

Level 4 — Expert opinion, tradition, and marketing

The base of the pyramid. A veterinarian’s opinion, a traditional use, a “formulated by experts” claim, or an internal feeding study with no control group. These may point in a useful direction, but they aren’t clinical evidence. This is the level at which phrases like “scientifically formulated” and “clinically inspired” live.

The important insight is that moving up the hierarchy is expensive and slow, which is exactly why so much marketing stays at the bottom. A systematic review or a canine RCT costs real money and time; citing a mouse study or an expert’s endorsement is nearly free.

Applying the Hierarchy to Supplement Categories

Postbiotics — Level 1 + Level 2

The postbiotic category has, unusually for a pet supplement space, reached the top of the pyramid. A 2025 systematic review and meta-analysis screened 157 records, included 69, and analyzed 13 in-vivo canine studies (Bonel-Ayuso et al., 2025; PMID: 40732081). Below that Level 1 capstone sit multiple Level 2 canine RCTs, which we detail in the next section. In honesty, the meta-analysis itself found no statistically significant pooled difference for fecal parameters — a signal that the field is young and heterogeneous — but the presence of a systematic review at all puts postbiotics a full level above most of the category.

Probiotics (general) — Level 2 for a few, Level 3-4 for most

A small number of probiotic products have genuine canine RCTs; FortiFlora’s SF68 strain is the most studied. But the category as a whole draws a sober verdict from veterinary reviewers. A 2017 JAVMA review concluded that “there currently is no definitive evidence that probiotics are effective for dogs with chronic diarrhea,” and that “a clear role for administration of probiotics to dogs and cats is not evident on the basis of the current literature” (Jugan et al., 2017; PMID: 28207322). A 2019 canine RCT found a 30-billion-CFU probiotic no better than placebo for acute diarrhea (Shmalberg et al., 2019; DOI: 10.3389/fvets.2019.00163), and a 2021 survey found probiotic effects on the healthy-dog microbiome were transient (Manson-Smith et al., 2021; DOI: 10.3389/fvets.2021.664318). The category has some Level 2 evidence at the top and a large mass of Level 3-4 marketing below it.

Joint supplements (glucosamine / chondroitin) — Level 2-3, mixed

Joint supplements are among the more studied categories, with a number of trials behind ingredients like glucosamine, chondroitin, and green-lipped mussel. The evidence is genuinely stronger than for many categories, though results are mixed and the most heavily marketed products have themselves faced label-accuracy scrutiny. We place the category around the Level 2-3 boundary: real clinical investigation, but not the clean, pooled Level 1 picture that postbiotics now have.

Multi-system / “all-in-one” wellness — mostly Level 3-4

The fast-growing all-in-one category is, with rare exceptions, thin on product-level canine trials. Most products in this space rest on ingredient extrapolation (Level 3) and formulation marketing (Level 4). Where a multi-system product is built on a postbiotic base with published canine RCTs, it inherits that stronger evidence; where it’s a blend of individually-studied ingredients with no product trial, it sits at Level 3-4.

Calming, skin, and specialty categories — mostly Level 3-4

Calming (ashwagandha, L-theanine, hemp), skin-and-coat, and other specialty supplements are dominated by ingredient-level and expert-opinion evidence. A few individual ingredients have human or animal-model research behind them; finished-product canine RCTs are rare. These categories sit firmly at Level 3-4.

The Category Evidence Master Table

The pattern is unmistakable. Strip away the marketing and the category with the strongest, most complete evidence stack — a systematic review sitting atop multiple canine RCTs — is postbiotics. Everything else is either mixed (joint, probiotics) or thin (multi-system, specialty).

Why Postbiotics Sit Higher Than Most

The postbiotic evidence base is worth detailing because it’s the exception that the rest of the category should be measured against. Postbiotics are defined by the ISAPP as “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host” (Salminen et al., 2021; DOI: 10.1038/s41575-021-00440-6). The Level 2 canine RCTs behind them include:

• Oral health / halitosis^[2]: a double-blind, placebo-controlled RCT (n=24, 14 days) in which a heat-treated postbiotic reduced volatile sulfur compounds by 27% versus placebo (p=0.004), with no adverse events (Sordillo et al., 2025; PMID: 40509062).
• Itching^[3] / gut-skin axis: a double-blind, placebo-controlled RCT (n=30, 28 days) in which an indole-rich postbiotic reduced scratching by 20% from baseline (p=0.032) and perceived itching by 27% versus placebo (p=0.02), and increased microbiome diversity (Sordillo et al., 2025; PMID: 40723482).
• Dental plaque: a placebo-controlled, double-blind 57-day trial (n=60) in which a heat-treated L. plantarum postbiotic reduced plaque accumulation by 10% at high dose (Florit-Ruiz et al., 2025; DOI: 10.3390/ani15111615).
• Gut health (live vs. heat-treated): a controlled canine trial showing both the live and heat-treated forms of B. animalis BPL1 were safe and increased fecal propionate (2024; DOI: 10.1093/jas/skae291).
• Immune function in senior dogs: controlled trials of a prebiotic-plus-postbiotic combination showing increased CD4+/CD8+ T-cell ratio (p<0.001) and microbiota modulation favoring SCFA-producing bacteria (Wambacq et al., 2024; DOI: 10.3389/fvets.2024.1392985; Wambacq et al., 2025; DOI: 10.1038/s41598-025-10280-y).

We will repeat the honest caveat, because honesty is the whole point of this exercise: the 2025 meta-analysis did not find a statistically significant pooled effect on fecal parameters, and the field is young and heterogeneous. What the evidence hierarchy tells you isn’t “postbiotics are proven to cure everything.” It tells you that postbiotics have been tested more rigorously, at a higher level of the pyramid, in the target species, than the alternatives — and that the research community has advanced far enough to pool the results and report the null findings candidly. That’s what a mature evidence base looks like.

Why Most “Clinically Formulated” Claims Live at Level 4

Now consider the phrase “scientifically formulated” through the lens of the hierarchy. What level of evidence does it assert? None, specifically. It gestures at science without claiming any particular rung of the pyramid. A product can be “scientifically formulated” on the strength of:

• a single in-vitro result on one ingredient (Level 3),
• a consultant’s professional opinion (Level 4),
• an internal, unpublished feeding study with no control (Level 4), or
• nothing more than the existence of related research somewhere (Level 4 by association).

This is why the phrase is so popular: it’s unfalsifiable. No regulator requires a “scientifically formulated” product to have cleared Level 1 or Level 2 scrutiny, because the phrase doesn’t actually assert that it has. We documented the same bait-and-switch in our review of which brands have published clinical trials: the gap between ingredient-level research and product-level proof is where most of the category’s marketing lives, and that gap is precisely the distance between Level 3-4 and Level 1-2 on the hierarchy.

How to Use the Hierarchy as a Consumer

You can apply the hierarchy yourself with a few simple questions:

1. What level is the cited evidence? A mouse study or petri-dish result is Level 3. A human trial is Level 2 — but in the wrong species. A canine RCT is Level 2 in the right species. A systematic review of canine studies is Level 1.
2. Is there a trial in dogs, on the actual product? Ingredient studies in other species don’t clear Level 2 for your dog’s supplement.
3. Has anyone pooled the evidence? A systematic review or meta-analysis (Level 1) is worth far more than any single study a brand chooses to highlight.
4. Are null findings reported? A credible evidence base reports what did not work. Marketing only ever cites the positive.

A product whose best evidence is a Level 3 ingredient study isn’t necessarily bad — but it isn’t “clinically proven,” and you’re entitled to know the difference. The hierarchy gives you a vocabulary for that difference.

Our Verdict and Why

We rate the claim that dog supplement categories are generally backed by strong clinical evidence MISLEADING. It isn’t FALSE that research exists — there’s real science touching nearly every category. But it’s misleading to present that research as strong clinical proof, because most of it sits at Level 3 or 4 of the evidence hierarchy: animal models, in-vitro work, ingredient extrapolation, and expert opinion. The phrase “scientifically formulated” belongs to that lower tier and doesn’t imply Level 1 or Level 2 validation.

The honest field is uneven. Joint supplements have genuine, if mixed, clinical investigation. Probiotics have a few well-studied products but draw a cautious efficacy verdict from veterinary reviewers. Multi-system and specialty categories are mostly thin. And the postbiotic category has assembled the most complete evidence stack in the space — a 2025 systematic review atop multiple canine RCTs — even as its pooled results continue to mature. When a brand tells you it’s “scientifically formulated,” you now know the question that exposes the real evidence level: which rung of the pyramid is that science on?

References

1. Bonel-Ayuso DP, et al. Effects of Postbiotic Administration on Canine Health: A Systematic Review and Meta-Analysis. Microorganisms. 2025;13(7):1572. PMID: 40732081.
2. Sordillo A, Casella L, Turcotte R, Sheth RU. A Novel Postbiotic Reduces Canine Halitosis. Animals (Basel). 2025;15(11):1596. PMID: 40509062.
3. Sordillo A, Casella L, Turcotte R, Sheth RU. An Indole-Rich Postbiotic Reduces Itching in Dogs. Animals (Basel). 2025;15(14):2019. PMID: 40723482.
4. Salminen S, Collado MC, Endo A, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nature Reviews Gastroenterology & Hepatology. 2021;18:649-667. DOI: 10.1038/s41575-021-00440-6.
5. Jugan MC, Rudinsky AJ, Parker VJ, Gilor C. Use of probiotics in small animal veterinary medicine. JAVMA. 2017;250(5):519-528. PMID: 28207322.
6. Shmalberg J, et al. A Randomized Double Blinded Placebo-Controlled Clinical Trial of a Probiotic or Metronidazole for Acute Canine Diarrhea. Frontiers in Veterinary Science. 2019;6:163. DOI: 10.3389/fvets.2019.00163.